Sol-Gel Technologies Ltd. SLGL 深 沪
已收盘 08-21 16:00:00 美东时间
77.73
-0.765
-0.97%
华盛通- 最 高81.92
- 今 开81.92
- 成交量 3.33万股
- 最 低 77.17
- 昨 收 78.495
- 总市值 2.54亿
- 52周最高 97.97
- 市盈率 静 --
- 换手率 1.02%
- 52周最低 22.0428
- 委 比 0.00%
- 总股本 326.90万
- 历史最高 210.00
- 量 比 0.58
- 振 幅 6.05%
- 历史最低 3.34
- 每 手 1
- 风险率 21.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sol-Gel Technologies Q2 EPS $(1.13) Beats $(2.31) Estimate, Sales $591.000K Beat $75.000K Estimate
Sol-Gel Technologies (NASDAQ:SLGL) reported quarterly losses of $(1.13) per share which beat the analyst consensus estimate of $(2.31) by 51.08 percent. This is a 127.1 percent decrease over earnings of $4.17 per share from the same period last year. The company reported quarterly sales of $591.000 ...
08-20 20:42
美股大行评级 | 伯恩斯坦上调Robinhood目标价从130美元升至160美元；纽约梅隆银行、Datadog、五三银行、旅行者财产险集团获多家机构上调评级
今日重点评级关注：Needham：维持Immuneering"买入"评级，目标价从11美元升至18美元；富瑞：维持塞德斯医疗"买入"评级，目标价从90美元升至100美元
07-21 11:36
HC Wainwright & Co. Reiterates Buy on Sol-Gel Technologies, Maintains $110 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Sol-Gel Technologies (NASDAQ:SLGL) with a Buy and maintains $110 price target.
07-20 19:22
美股大行评级 | 瑞银上调超微公司目标价从455美元升至670美元，上调ARM目标价从260美元升至470美元；美银证券上调台积电目标价从490美元升至590美元
今日重点评级关注：Jones Trading：维持Definium Therapeutics"买入"评级，目标价从61美元升至74美元；韦德布什：维持Cerebras Systems"跑赢大市"评级，目标价从270美元升至280美元
06-25 11:32
Mizuho Initiates Coverage On Sol-Gel Technologies with Outperform Rating, Announces Price Target of $285
Mizuho analyst Uy Ear initiates coverage on Sol-Gel Technologies (NASDAQ:SLGL) with a Outperform rating and announces Price Target of $285.
06-24 18:07
Sol-Gel Technologies Q1 EPS $(1.31) Beats $(1.84) Estimate, Sales $108.000K Miss $900.000K Estimate
Sol-Gel Technologies (NASDAQ:SLGL) reported quarterly losses of $(1.31) per share which beat the analyst consensus estimate of $(1.84) by 28.8 percent. This is a 59.06 percent increase over losses of $(3.20) per share
05-28 20:38
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers ENvue Medical (NASDAQ:FEED) shares increased by 59.4% to $2.28 during T...
03-25 01:05
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering
Sol-Gel Technologies Ltd. announced the pricing of an underwritten offering of 459,112 ordinary shares at $72.00 per share, raising approximately $33.1 million. The funds will support the development of SGT-610, a Phase 3 topical hedgehog inhibitor for Gorlin syndrome, with potential applications in high-frequency basal cell carcinoma. The offering includes participation from notable investors and is expected to close on March 25, 2026. Sol-Gel i...
03-24 01:38
Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025
Sol-Gel Technologies Ltd. filed its annual report on Form 20-F for 2025, available on the SEC website and its investor relations site. The company is advancing rare skin disease therapies, including SGT-610, a Phase 3 topical hedgehog inhibitor for Gorlin syndrome patients, and SGT-210, a topical EGFR inhibitor. Sol-Gel also markets FDA-approved dermatology products TWYNEO® and EPSOLAY®.
03-19 12:53
